Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28396661 | 0.83 | IDO1 (0.44) | C3AR1IDO1MIFTRPA1CYP1A2 | |
| SCHEMBL23342356 | 0.83 | SLC6A2 (0.41) | C3AR1IDO1MIFTRPA1TAAR1 | |
| SCHEMBL1883321 | 0.82 | MIF (0.50) | MIFTRPA1CYP1A2CYP2A6TAAR1 | |
| SCHEMBL8851006 | 0.73 | IDO1 (0.42) | C3AR1IDO1CYP1A2CYP2A6TAAR1 | |
| SCHEMBL436823 | 0.73 | IDO1 (0.42) | C3AR1IDO1MIFTRPA1CYP1A2 | |
| SCHEMBL23342427 | 0.72 | SCN4A (0.31) | CYP1A2MAOACYP3A4 | |
| SCHEMBL1706732 | 0.71 | MIF (0.63) | C3AR1IDO1MIFTRPA1CYP1A2 | |
| SCHEMBL19987607 | 0.71 | IDO1 (0.41) | C3AR1IDO1MIFTRPA1CYP1A2 | |
| SCHEMBL25895358 | 0.71 | ACHE (0.41) | HPGDALDH1A1CYP3A4ACHETDP1 | |
| SCHEMBL23341664 | 0.70 | TAAR1 (0.37) | TAAR1HPGDSMN1; SMN2ALDH1A1CTBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | C3AR1 3029/4885IDO1 4657/4885MIF 2076/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | C3AR1 3387/4885IDO1 4649/4885MIF 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.